UBS AM’s Dianthus Therapeutics DNTH Stock Holding History

UBS AM’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.07M	Buy	60,435 +48,362	+401%	+$2.8M	﹤0.01%	1550
2025 Q4	$498K	Buy	+12,073	New	+$468K	﹤0.01%	2320
2024 Q3	–	Sell	-10,152	Closed	-$263K	–	2813
2024 Q2	$263K	Buy	+10,152	New	+$244K	﹤0.01%	2741
2021 Q4	–	Sell	-31,971	Closed	-$3.72M	–	2865
2021 Q3	$3.72M	Sell	31,971 -719	-2%	-$83.8K	﹤0.01%	1499
2021 Q2	$5.12M	Sell	32,690 -2,385	-7%	-$438K	﹤0.01%	1355
2021 Q1	$6.64M	Buy	35,075 +221	+0.6%	+$37.2K	﹤0.01%	1224
2020 Q4	$4.37M	Sell	34,854 -3,244	-9%	-$368K	﹤0.01%	1354
2020 Q3	$4.15M	Buy	38,098 +598	+2%	+$70.9K	﹤0.01%	1228
2020 Q2	$4.51M	Buy	+37,500	New	+$5.28M	﹤0.01%	1157

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS AM's DNTH Position: Q1 2026 in Review

UBS AM increased its Dianthus Therapeutics (DNTH) stake by 401% in Q1 2026, buying an estimated $2.8M and bringing the position to 60,435 shares worth $5.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1550.

UBS AM first reported a position in DNTH in Q2 2020 and has held it in 9 quarters since. The position peaked at $6.64M in Q1 2021. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

UBS AM held 60,435 shares of Dianthus Therapeutics worth $5.07M as of Q1 2026.
UBS AM bought 48,362 Dianthus Therapeutics shares in Q1 2026, an estimated $2.8M.
Dianthus Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1550 holding.
UBS AM first reported a position in Dianthus Therapeutics in Q2 2020 and has held it in 9 quarters since.
UBS AM's Dianthus Therapeutics position peaked at $6.64M in Q1 2021.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.